Editas Medicine, Inc.EDITEarnings & Financial Report

Nasdaq · pharmaceutical industry

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

NextMar 19, 2026

Revenue

$7.5M

Gross Profit

N/A

Operating Profit

$-24.5M

Net Profit

$-25.1M

Gross Margin

N/A

Operating Margin

-325.4%

Net Margin

-333.0%

YoY Growth

12265.6%

EPS

$-0.28

Financial Flow

Editas Medicine, Inc. Q3 2025 Financial Summary

Editas Medicine, Inc. reported revenue of $7.5M for Q3 2025, with a net profit of $-25.1M (-333.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$7.5M
Net Profit	$-25.1M
Gross Margin	N/A
Operating Margin	-325.4%
Report Period	Q3 2025

Editas Medicine, Inc. Annual Revenue by Year

Editas Medicine, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $32.3M).

Year	Annual Revenue
2024	$32.3M
2023	$78.1M
2022	$19.7M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$60.0M	$1.1M	$513000	$61000	$30.6M	$4.7M	$3.6M	$7.5M
YoY Growth	818.6%	-88.5%	-82.2%	-98.9%	-49.0%	310.4%	597.5%	12265.6%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$499.2M	$440.3M	$384.8M	$327.6M	$341.6M	$263.7M	$210.6M	$201.8M
Liabilities	$150.1M	$145.9M	$152.8M	$151.9M	$207.3M	$201.2M	$191.4M	$188.3M
Equity	$349.1M	$294.4M	$232.0M	$175.6M	$134.3M	$62.4M	$19.2M	$13.5M